Lipoxin B4
Based on 1 Customer Validation
Lipoxin B4 (LXB4) is a structurally distinct product of arachidonic acid metabolism. Lipoxin B4 reduces leukocyte infiltration and mucus secretion in the nasal mucosa and decreases mast cell and eosinophil degranulation in the upper airway. Lipoxin B4 decreases airway inflammation, mucus metaplasia and hyper- responsiveness in the lower airway. Lipoxin B4 shows mucosal protective actions and has the potential for the research of allergic inflammation in the upper and lower airways.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.2%
- CAS 番号: 98049-69-5
- 分子式: C20H32O5
- 分子量:352.47
-
保管条件:
Solution, -20°C, 2 years
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-113509
Lipoxin A4Anti-inflammatory Agent -
HY-113509B
15(R)-Lipoxin A4Specialized Pro-resolving Mediator -
HY-126722
Lipoxin A4 methyl esterLipoxin Analog -
HY-113492
5(S)15(S)-DiHETEPlatelet Aggregation Inhibitor -
HY-100450
BML-111Lipoxin A4 Receptor Agonist -
HY-130239
14(S)-HDHADHA Oxygenation Product -
HY-113884B
(S)-Coriolic acidPPARγ Activator/Mitochondrial Dysfunction Inducer -
HY-115381
Lipoxin A5Endogenous Metabolite -
HY-130429
14,15-Leukotriene C4Leukotrienes -
HY-113483
20-Carboxy-Leukotriene B4LTB4 Metabolite -
HY-113490
15-KETE -
HY-118149
9(S)-HpODE
Endogenous Metabolite アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
|
Human Endogenous Metabolite |
化学情報
-
CAS 番号 98049-69-5
-
性状 Liquid
-
分子量 352.47
-
分子式 C20H32O5
-
Color Colorless to light yellow
-
SMILES
CCCCC[C@H](O)[C@H](O)/C=C/C=C/C=C\C=C\[C@@H](O)CCCC(O)=O
-
別名
LXB4
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Solution, -20°C, 2 years
プロトコル
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (545 KB)
- English - EN (545 KB)
- Français - FR (545 KB)
- Deutsch - DE (545 KB)
- Norwegian - NO (545 KB)
- Español - ES (545 KB)
- Swedish - SV (545 KB)
- Italian - IT (545 KB)
- Korean - KR (545 KB)
- Portuguese - PT (545 KB)
-
取扱説明書 (2659 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Lipoxin B4 関連分類
HY-116953 関連分類
Powered by Bioz